BCTX

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations will feature BriaCell's personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro's research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612 ).

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing Program builds on BriaCell's experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in the US in 2026 PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a key genetic engineering milestone, advancing the program toward clinical development. Bria-MEL+ is a cell-based therapeutic cancer vaccine designed to harness a patient's own immune system to combat melanoma.

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluation of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for prostate cancer. “We are pleased to announce FDA clearance of the IND for Bria-PROS+, our next-generation personalized immunotherapy for prostate cancer,” stated Dr. William V.

PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier:  NCT06072612 ).

PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.

PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has entered into a Memorandum of Understanding (“MoU”), with Uneedle, a microneedle based drug-delivery device company in the Netherlands, to support the continued use and commercial readiness of Uneedle's proprietary microneedle technology for intradermal administration of BriaCell's lead Phase 3 clinical candidate, Bria-IMT, for the treatment of metastatic breast cancer.

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share. All of the common shares in the offering were offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, were approximately $4.7 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST analysis, which measures time without disease symptoms or significant treatment-related toxicity, showed clinically meaningful benefit in heavily pre-treated MBC patients in the ongoing Phase 3 study Biomarker analyses from the ongoing Phase 3 study further validates potential predictors of anti-cancer response initially reported in Phase 2 study 2026 ASCO Annual Meeting, May 29-June 2, 2026, at McCormick Place, Chicago, Illinois PHILADELPHIA and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces positive clinical data from three clinical data poster presentations at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations will include two poster presentations featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612 ) and one poster highlighting further analyses of Phase 2 data.